Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma

Zarwa Yaseen; Tuba N Gide; Jordan W Conway; Alison J Potter; Camelia Quek; Angela M Hong; Georgina V Long; Richard A Scolyer; James S Wilmott

doi:10.3389/fmolb.2022.810858

Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma

Front Mol Biosci. 2022 May 19:9:810858. doi: 10.3389/fmolb.2022.810858. eCollection 2022.

Authors

Zarwa Yaseen^{1

2

3}, Tuba N Gide^{1

2

3}, Jordan W Conway^{1

2

3}, Alison J Potter^{1

2

4

5}, Camelia Quek^{1

2

3}, Angela M Hong^{1

3

6}, Georgina V Long^{1

2

3

7

8}, Richard A Scolyer^{1

2

3

4}, James S Wilmott^{1

2

3}

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
² Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
³ Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
⁴ Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.
⁵ Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
⁶ GenesisCare, Radiation Oncology, Mater Hospital, Sydney, NSW, Australia.
⁷ Royal North Shore Hospital, Sydney, NSW, Australia.
⁸ Mater Hospital, Sydney, NSW, Australia.

Abstract

Multiplex immunofluorescence staining enables the simultaneous detection of multiple immune markers in a single tissue section, and is a useful tool for the identification of specific cell populations within the tumour microenvironment. However, this technology has rarely been validated against standard clinical immunohistology, which is a barrier for its integration into clinical practice. This study sought to validate and investigate the accuracy, precision and reproducibility of a multiplex immunofluorescence compared with immunohistochemistry (IHC), including tissue staining, imaging and analysis, in characterising the expression of immune and melanoma markers in both the tumour and its microenvironment. Traditional chromogenic IHC, single-plex immunofluorescence and multiplex immunofluorescence were each performed on serial tissue sections of a formalin-fixed paraffin-embedded (FFPE) tissue microarray containing metastatic melanoma specimens from 67 patients. The panel included the immune cell markers CD8, CD68, CD16, the immune checkpoint PD-L1, and melanoma tumour marker SOX10. Slides were stained with the Opal^™ 7 colour Kit (Akoya Biosciences) on the intelliPATH autostainer (Biocare Medical) and imaged using the Vectra 3.0.5 microscope. Marker expression was quantified using Halo v.3.2.181 (Indica Labs). Comparison of the IHC and single-plex immunofluorescence revealed highly significant positive correlations between the cell densities of CD8, CD68, CD16, PD-L1 and SOX10 marker positive cells (Spearman's rho = 0.927 to 0.750, p < 0.0001). Highly significant correlations were also observed for all markers between single-plex immunofluorescence and multiplex immunofluorescence staining (Spearman's rho >0.9, p < 0.0001). Finally, correlation analysis of the three multiplex replicates revealed a high degree of reproducibility between slides (Spearman's rho >0.940, p < 0.0001). Together, these data highlight the reliability and validity of multiplex immunofluorescence in accurately profiling the tumour and its associated microenvironment using FFPE metastatic melanoma specimens. This validated multiplex panel can be utilised for research evaluating melanoma and its microenvironment, such as studies performed to predict patient response or resistance to immunotherapies.

Keywords: immunohistochemistry; immunotherapy; melanoma; multiplex immunofluorescence; multispectral imaging; pathology; predictive biomarker; tumour microenvironment.